DSG teams up with pharmaceutical technology company to speed early detection of major diseases

Jan 12 2010

DSG, a leader in electronic data capture (EDC) has teamed up with a leading-edge pharmaceutical technology company to speed the early detection of Alzheimer’s, Parkinson’s, and Diabetes.

“We are delighted to provide this Pharma leader with the latest critical technology solutions, helping to reach an incredibly important goal – the early detection of debilitating diseases”

The focus is on developing molecular imaging products that are leading the way to the early detection of human diseases. DSG’s eCaseLink™ EDC (Electronic Data Capture) supports three current clinical trials for Alzheimer’s disease, Parkinson’s disease and Diabetes. eCaseLink™ supplies real-time capability to review case documents and metrics across all study sites, significantly increasing clinical trial management speed, while reducing study management costs by as much as 30 percent.

DSG’s eCaseLink™ allows the pharmaceutical diagnostic and therapeutic company not only to collect and manage their data in real time, but it also gives them the option to add needed functionality as studies progress. They have found that the innovation of the eCaseLink™ product suite, combined with the experience and dedication of the DSG team, is paying immediate and continued dividends for their clinical trial management process.

“We are delighted to provide this Pharma leader with the latest critical technology solutions, helping to reach an incredibly important goal – the early detection of debilitating diseases,” said Tony Varano, CEO, DSG, Inc. “What is especially gratifying is that DSG provides select solution modules specific to their needs, rather than the ‘cookie cutter’ approach to most clinical trial data collection solutions.”